A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function

Phase 1 Completed 32 enrolled AstraZeneca

Non-randomizedParallel-groupOpen-labelBasic science

Summary

A study to evaluate the amount of fostamatinib in the blood in subjects with impaired hepatic (liver) function compared with healthy volunteers with normal liver function. The study will also evaluate safety and tolerability in subjects with hepatic impairment.

Timeline

Start: 2010-10
Primary completion: 2011-06
Completion: 2011-06

Publications

Martin P, Oliver S, Gillen M, Marbury T, Millson D. Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies. Clin Ther. 2015 Dec 1;37(12):2823-36. doi: 10.1016/j.clinthera.2015.09.016. Epub 2015 Oct 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fostamatinib	Small molecule	150 mg	Oral

Indications

No indication recorded.